Sort
15,842 grants matching “pancreatic cancer”
Novobiocin-mediated polymerase theta inhibition in homologous recombination repair-deficient cancers
$414,529Geoffrey I Shapiro · Dana-Farber Cancer Inst · R01 · FY2022 · CA
FoxO signaling and skeletal muscle atrophy
$414,489Andrew Robert Judge · University Of Florida · R01 · FY2019 · AR
Redox Modification and Targeting of Mutant KRas in Cancer
$414,152Kate Suzanne Carroll · Scripps Florida · R01 · FY2019 · CA
Indiana University (IU) Clinical Center for Chronic Pancreatitis Clinical Research Network
$414,014Evan L Fogel · Indiana University Indianapolis · U01 · FY2018 · DK
Project 3: Chronic interferon and bile acid signaling as drivers of immunosuppression in age-related liver cancer
$413,965Susan M Kaech · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2024 · AG
Mechanisms of diabetic amyloid formation via 2D IR spectroscopy
$413,923Martin T Zanni · University Of Wisconsin-Madison · R01 · FY2024 · DK
Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer
$413,920Jonathan Maybaum · University Of Michigan At Ann Arbor · R01 · FY2010 · CA
Pharmacodynamics of Gemcitabine by MRS in Pancreatic CA
$413,822Howard S Hochster · New York University School Of Medicine · R01 · FY2007 · CA
Molecular mechanisms of Hedgehog receptor function
$413,584Philip A Beachy · Stanford University · R01 · FY2019 · GM
Molecular mechanisms of Hedgehog receptor function
$413,584Philip A Beachy · Stanford University · R01 · FY2020 · GM
CHARM 2: Chemotherapy for ablation and resolution of mucinous pancreatic cysts: a prospective, randomized, double-blind, multi-center clinical trial
$413,443Matthew T. Moyer · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2019 · CA
Targeting PKR-Bcl2 Signaling to Overcome Paclitaxel Resistance in Ovarian Cancer
$413,431Jixin Dong · University Of Nebraska Medical Center · R01 · FY2022 · CA
Accelerating biomarker development through novel statistical methods for analyzing phase III/IV studies
$413,415Ying Huang · Fred Hutchinson Cancer Center · R01 · FY2023 · CA
Alaska Native Tumor Registry as SEER Registry
$413,281National Cancer Institute · Y01 · FY2009 · CA
CHARM 2: Chemotherapy for ablation and resolution of mucinous pancreatic cysts: a prospective, randomized, double-blind, multi-center clinical trial
$413,177Matthew T. Moyer · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2021 · CA
Targeting aberrant enhancer landscapes in pancreatic cancer
$413,053Christopher Vakoc · Cold Spring Harbor Laboratory · R01 · FY2021 · CA
Targeting aberrant enhancer landscapes in pancreatic cancer
$413,053Christopher Vakoc · Cold Spring Harbor Laboratory · R01 · FY2019 · CA
Targeting aberrant enhancer landscapes in pancreatic cancer
$413,053Christopher Vakoc · Cold Spring Harbor Laboratory · R01 · FY2020 · CA
FoxO signaling and skeletal muscle atrophy
$413,043Andrew Robert Judge · University Of Florida · R01 · FY2018 · AR
Role of Reactive Oxygen Species in Lymphocyte Development and Function
$412,732Thomas Leto · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
FoxO signaling and skeletal muscle atrophy
$412,725Andrew Robert Judge · University Of Florida · R01 · FY2021 · AR
Project 1 â IL-6/STAT3/NF-kB in Adipose-Muscle Crosstalk in the Pancreatic Cancer Macroenvironment
$412,656Teresa A Zimmers · Medical University Of South Carolina · P01 · FY2024 · CA
Pancreatic Cancer Vulnerabilities Downstream of Cooperating Oncogenic Mutations
$412,619Hartmut Land · University Of Rochester · R01 · FY2015 · CA
Pancreatic Cancer Vulnerabilities Downstream of Cooperating Oncogenic Mutations
$412,619Hartmut Land · University Of Rochester · R01 · FY2014 · CA
Biochemical, molecular, and dietary studies for pancreatic cancer within PLCO
$412,556Rachael Stolzenberg-Solomon · Division Of Cancer Epidemiology And Genetics · ZIA · FY2011 · CA